Publikationen 2016

Developments in Advanced Prostate Cancer in 2016
Martin JP Hennig, Nils Gilbert, Axel S Merseburger
European Oncology & Haematology, 2016;12(1):17–8 DOI: http://doi.org/10.17925/EOH.2016.12.01.17

Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study.
Frantzi M, Van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.
Clin Cancer Res. 2016 Mar 29. pii: clincanres.2715.2015. [Epub ahead of print]
PMID: 27026199

68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.
Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, Christiansen H, Merseburger AS, Bengel FM.
Eur Radiol. 2016 Mar 24. [Epub ahead of print]
PMID: 27011373

Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference.
Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S.
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):39-44. doi: 10.5489/cuaj.3322.
PMID: 26977205

Select item 26916953[ ]4.
Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
Makboul R, Refaiy A, Abdelkawi IF, Hameed DA, Elderwy AA, Shalaby MM, Merseburger AS, Hussein MR.
Pathol Res Pract. 2016 May;212(5):385-92. doi: 10.1016/j.prp.2016.02.008. Epub 2016 Feb 9.
PMID: 26916953

Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus.
Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, Hora M, Powles T, Merseburger AS, Kuczyk MA, Bensalah K, Mulders PF, Ljungberg B, Lam TB.
Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01205-1. doi: 10.1016/j.eururo.2015.11.034. [Epub ahead of print] Review.
PMID: 26707869

[Cardiovascular risk patients under androgen deprivation therapy : Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS, Sedding D, Hüter K.
Urologe A. 2016 Feb;55(2):218-25. doi: 10.1007/s00120-015-0013-1. German.
PMID: 26637324

Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV. Inhibition of IGF-1R Diminishes Transcriptional Activity of the Androgen Receptor and its Constitutively Active, C-Terminally Truncated Counterparts Q640X and AR-V7. World J Urol (2016) 34: 633-639.

Peters I, Dubrowinskaja N, Tezval H, Kramer MW, von Klot CA, Hennenlotter J, Stenzl A, Scherer R, Kuczyk MA, Serth J. Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma. Target Oncol (2015) 10: 267-275.

Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget (2015) DOI: 10.18632/oncotarget.3925

Peters I, Tezval H, Kramer MW, Wolters M, Grünwald V, Kuczyk MA, Serth J. Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures. Aktuelle Urol (2015)  46: 481-485.

Schrader AJ, Boegemann M, Ohlmann C-H, Schnoeller TJ, Krabbe L-M, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann

E, Cronauer MV. Enzalutamide in castration resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2014) 65: 30-36.

Streicher W, Lüdeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG,. Schrader AJ, Cronauer MV. Stilbene induced inhibition of androgen receptor dimerization: Implications for AR and ARΔLBD-signaling in human prostate cancer cells. PLoS ONE (2014) 9: e98566.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB. Differential expression of SDF-1 isoforms in bladder cancer. J Urol (2014) 191: 1899-18905.

Fischer K, Theil G, Hoda R, Fornara P. Missing agreement between the two IMMULITE® PSA assays. Clin Chem Lab Med (2013) 51: e37-e39.

Laschak M, Spindler K-D, Schrader A.J, Hessenauer A, Streicher W, Schrader M, Cronauer MV. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells BMC Cancer (2012) 12: 130.

Hoda MR,Theil G, Mohammed N, Fischer K, Fornara P.  The adipocyte-derived hormone leptin has prolifer

ative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J Oncol (2012) https://www.hindawi.com/journals/jo/2012/280386/

Jain G, Voogt C, Tobias A, Spindler K-D, Möller P, Cronauer MV*, Marienfeld RB*. IkappaB-Kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia (2012) 14: 178-189.    -*shared senior author-ship-

Hoda MR, Hamza A, Fischer K, Wagner S, Schneider J, Fornara P. Übergewicht als Risikofaktor für Prostatakarzinom: Rolle der Adipozytokine und Beteiligung der Tyrosinkinasen. Aktuelle Urol (2010), 41: 178-183.

Greco F*, Hoda MR*, Wagner S, Reichelt O, Inferrera A, Fischer K, Fornara P. Adipocytokine: A New Family of Inflammatory and Immunologic Markers of Invasiveness in Major Urologic Surgery. Eur Urol  (2010)  58: 781-787  -*equal contribution -

Azoitei A, Merseburger AS, Godau B, Hoda MR, Schmid E, Cronauer MV. C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2017) 166: 38-44.

Hoda MR, Kramer MW,Merseburger AS, Cronauer MV. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother (2017) 18: 105-113.

Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol (2015) 12: 317-330.

Hoda MR, Mohammed N, Theil G, Fischer K, Fornara P.  Übergewicht und Prostatakarzinom. Urologe A (2012) 51: 1253-1260.

PraxisSkills Allgemeinmedizin: Medizinische Prozeduren für die Hausarztpraxis - griffbereit - Videos zum klinisch-praktischen Vorgehen. Taschenbuch – 24. August 2016, 248 Seiten,Schattauer; Auflage: 1 (24. August 2016), ISBN-13: 978-3794531400, Dr. Markus Schäfer, Kapitel Urogenitaltrakt

P. Fornara, M.R. Hoda, K. Fischer. Prostatakarzinom – Diagnostik In: Uro-Onkologie, H. Rübben (Hrsg.); pp. 554-570, 6. Auflage; 2014, Springer-Verlag

K-D Spindler, M Laschak and M.V. Cronauer.  Nitric oxide – a tool to block nuclear receptor activity, In: Nuclear Receptors, Margaret K. Bates and Regina M. Kerr (Editors); pp. 87-102, Nova Publishers 2011.